{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:39:41Z","timestamp":1759228781188},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1097\/ico.0000000000000548","type":"journal-article","created":{"date-parts":[[2015,8,12]],"date-time":"2015-08-12T14:02:45Z","timestamp":1439388165000},"page":"1295-1302","source":"Crossref","is-referenced-by-count":8,"title":["Inhibition of Pathologic Corneal Neovascularization by Topical Application of a Novel Peptide In Vivo"],"prefix":"10.1097","volume":"34","author":[{"given":"Yi","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-19-20210204","first-page":"214","article-title":"Corneal blindness: a global perspective.","volume":"79","author":"Whitcher","year":"2001","journal-title":"Bull World Health Organ"},{"key":"R2-19-20210204","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1634\/stemcells.2007-0737","article-title":". The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury.","volume":"26","author":"Oh","year":"2008","journal-title":"Stem Cells"},{"key":"R3-19-20210204","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000048289","article-title":"Corneal allograft rejection: current understanding.","volume":"216","author":"Bertelmann","year":"2002","journal-title":"Ophthalmologica"},{"key":"R4-19-20210204","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1016\/S0021-9258(19)49853-0","article-title":"Angiogenesis.","volume":"267","author":"Folkman","year":"1992","journal-title":"J Biol Chem"},{"key":"R5-19-20210204","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/ICO.0b013e318201405a","article-title":"Treatments for corneal neovascularization: a review.","volume":"30","author":"Gupta","year":"2011","journal-title":"Cornea"},{"key":"R6-19-20210204","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/jama.293.12.1509","article-title":"Inhibitors of ocular neovascularization: promises and potential problems.","volume":"293","author":"van Wijngaarden","year":"2005","journal-title":"JAMA"},{"key":"R7-19-20210204","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":". Pegaptanib for neovascular age-related macular degeneration. VEGF inhibition study in ocular neovascularization clinical trial group.","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Eng J Med"},{"key":"R8-19-20210204","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":". Corneal neovascularization: an anti-VEGF therapy review.","volume":"57","author":"Chang","year":"2012","journal-title":"Surv Ophthalmol"},{"key":"R9-19-20210204","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1167\/iovs.06-0828","article-title":". Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.","volume":"48","author":"Inan","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R10-19-20210204","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdl161","article-title":". A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200.","volume":"17","author":"Giantonio","year":"2006","journal-title":"Ann Oncol"},{"key":"R11-19-20210204","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":". Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R12-19-20210204","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2174\/138161207781039715","article-title":"Developing antiangiogenic peptide drugs for angiogenesis-related diseases.","volume":"13","author":"Sulochana","year":"2007","journal-title":"Curr Pharm Des"},{"key":"R13-19-20210204","first-page":"155","article-title":". Antiangiogenic peptides and proteins: from experimental tools to clinical drugs.","volume":"1765","author":"Ruegg","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"R14-19-20210204","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2183\/pjab.86.588","article-title":"The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine.","volume":"86","author":"Nakamura","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"R15-19-20210204","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1167\/iovs.06-0923","article-title":". Hepatocyte growth factorscatter factor promotes retinal angiogenesis through increased urokinase expression.","volume":"48","author":"Colombo","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-19-20210204","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/bjo.83.7.763","article-title":"A role for hepatocyte growth factor in diabetic retinopathy.","volume":"83","author":"Boulton","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"R17-19-20210204","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0002-9440(10)65004-3","article-title":". Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity.","volume":"156","author":"Lashkari","year":"2000","journal-title":"Am J Pathol"},{"key":"R18-19-20210204","first-page":"S9","article-title":". Hepatocyte growth factor vascular endothelial growth factor are elevated in subretinal fluid from advanced retinopathy of prematurity.","volume":"40","author":"Lashkari","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-19-20210204","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00417-013-2370-z","article-title":". KGF, FGFb, VEGF, HGF and TGF1 secretion of human keratocytes following photodynamic inactivation (PDI) in vitro.","volume":"251","author":"Stachon","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R20-19-20210204","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.2353\/ajpath.2009.080597","article-title":". Alternative proteolytic processing of hepatocyte growth factor during wound repair.","volume":"174","author":"Buchstein","year":"2009","journal-title":"Am J Pathol"},{"key":"R21-19-20210204","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/1568011023353705","article-title":"Kringle structures and antiangiogenesis.","volume":"2","author":"Cao","year":"2002","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"R22-19-20210204","first-page":"6737","article-title":". HGFNK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.","volume":"60","author":"Kuba","year":"2000","journal-title":"Cancer Res"},{"key":"R23-19-20210204","doi-asserted-by":"crossref","first-page":"11449","DOI":"10.1074\/jbc.M212358200","article-title":". Antiangiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.","volume":"278","author":"Kim","year":"2003","journal-title":"J Biol Chem"},{"key":"R24-19-20210204","first-page":"7518","article-title":". Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model.","volume":"61","author":"Tomioka","year":"2001","journal-title":"Cancer Res"},{"key":"R25-19-20210204","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1182\/blood-2006-02-003103","article-title":". NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor.","volume":"109","author":"Du","year":"2007","journal-title":"Blood"},{"key":"R26-19-20210204","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1006\/bbrc.2000.4034","article-title":". Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells.","volume":"279","author":"Kuba","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"R27-19-20210204","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1006\/bbrc.2000.3658","article-title":". Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis.","volume":"277","author":"Xin","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"R28-19-20210204","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/0008-5472.CAN-07-2081","article-title":". The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma.","volume":"68","author":"Shen","year":"2008","journal-title":"Cancer Res"},{"key":"R29-19-20210204","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1158\/1535-7163.MCT-08-0366","article-title":". AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer.","volume":"7","author":"Nie","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"R30-19-20210204","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3341\/kjo.2010.24.4.230","article-title":"The effect of bevacizumab on corneal neovascularization in rabbits.","volume":"24","author":"Kim","year":"2010","journal-title":"Korean J Ophthalmol"},{"key":"R31-19-20210204","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/ijc.24027","article-title":". A novel peptide from human apolipoprotein (a) inhibits angiogenesis and tumor growth by targeting c-Scr phosphorylation in VEGF-induced human umbilical endothelial cell.","volume":"124","author":"Yi","year":"2009","journal-title":"Int J Cancer"},{"key":"R32-19-20210204","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1111\/j.1755-3768.2012.02476.x","article-title":"Inhibition of ocular neovascularization by a novel peptide derived from human placenta growth factor-1.","volume":"90","author":"Zheng","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"R33-19-20210204","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1006\/exer.1997.0292","article-title":"Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.","volume":"64","author":"Kenyon","year":"1997","journal-title":"Exp Eye Res"},{"key":"R34-19-20210204","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/path.1788","article-title":". A comparative study of endothelial cell markers expressed in chronically inflamed human tissues: MECA-79, Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146.","volume":"206","author":"Middleton","year":"2005","journal-title":"J Pathol"},{"key":"R35-19-20210204","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000337139","article-title":". Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.","volume":"48","author":"Oner","year":"2012","journal-title":"Ophthalmic Res"},{"key":"R36-19-20210204","first-page":"104","article-title":". Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.","volume":"17","author":"Rocher","year":"2011","journal-title":"Mol Vis"},{"key":"R37-19-20210204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":". Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R38-19-20210204","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":". Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000000548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:12:47Z","timestamp":1620954767000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201510000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000000548","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}